Skip to main content

Table 1 Baseline characteristics

From: Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

Baseline characteristics Placebo (n = 8) Dapagliflozin 10 mg (n = 8) P value
Male sex, N (%) 5 (62.5) 8 (100)  
Age, years 67 ± 2.2 66 ± 2.6 P = 0.7
Diabetes duration, years 8.25 ± 0.6 6.3 ± 1.0 P = 0.2
HbAlc, % 8.1 ± 0.2 7.8 ± 0.1 P = 0.45
Fasting glycemia (mg/dl) 136 ± 17 140 ± 12 P = 0.5
C-peptide (ng/ml) 1.4 ± 0.3 1.7 ± 0.2 P = 0.6
BMI, kg/m2 28.5 ± 1.0 27.3 ± 1.1 P = 0.3
Body weight, kg 81.8 ± 4.7 81.8 ± 2.6 P > 0.9
Heart rate, bpm 61 ± 4 65 ± 4 P = 0.9
Systolic BP, mmHg 135 ± 5.2 143 ± 5.1 P = 0.2
Diastolic BP, mmHg 71 ± 3.8 68 ± 4.4 P = 0.4
CAD (previous PCl/no PCI) 4/4 3/5 P = 0.3
eGFR (ml/min) 90.6 ± 3.1 85.8 ± 6.2 P = 0.5
Medications    
Metformin 8 (100) 7 (87.5)  
DPP- 4i 4 (50) 3 (37.5)
GLP-1RA 2 (25) 1 (12.5)
Basal insulin 2 (25) 3 (37.5)
Sulfonylurea 2 (25) 1(12.5)
  1. Data are mean ± SEM. HbA1c, glycated hemoglobin; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate